Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • The company has poor fundamentals for a short-term investment strategy.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at USD 177.19 USD in weekly data.
  • The close medium term support offers good timing for purchasing the stock.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • Low profitability weakens the company.
  • One of the major weak points of the company is its financial situation.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the past seven days, analysts have been lowering their EPS expectations for the company.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The underlying tendency is negative on the weekly chart below the resistance at 221.81 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ALLERGAN PLC-10.89%62 565
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
MERCK AND COMPANY7.68%172 423
AMGEN25.17%135 858
SANOFI8.71%124 607
BAYER19.19%115 363
CELGENE CORPORATION17.89%108 637
BRISTOL-MYERS SQUIBB COMPAN..11.72%105 250
GLAXOSMITHKLINE-2.94%98 264
NOVO NORDISK A/S16.92%96 545
ABBOTT LABORATORIES42.28%95 664
ELI LILLY AND COMPANY17.68%94 751
ASTRAZENECA15.54%86 638
More Results
Financials ($)
Sales 2017 15 892 M
EBIT 2017 7 621 M
Net income 2017 -3 982 M
Debt 2017 24 536 M
Yield 2017 1,56%
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 5,48x
EV / Sales 2018 5,15x
Capitalization 62 565 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ALLERGAN PLC
Duration : Period : Day
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Duration : Period : Week
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders